Roche v. Promega PCR Taq patent validity trial will examine Cetus' conduct in obtaining patent.
This article was originally published in The Gray Sheet
ROCHE V. PROMEGA TRIAL ON PCR TAQ ENZYME PATENT VALIDITY will seek to determine if Cetus, from which Roche acquired the technology, procured a Taq polymerase patent by "inequitable conduct." "Efficiency will best be served in this case by proceeding to trial as soon as possible on the issue of Cetus' intent to mislead [the Patent Trade Office]," Northern California U.S. District Court Judge Vaughn R. Walxer ruled in an Aug. 9 order. Walxer set a case management conference for Sept. 13, at which time a trial date will be set.
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.